Join our upcoming webinar to learn about the MSDA Test in a clinical setting on Dec. 13, 12:00 PM EST Register Today

Get in Touch

Octave at the ECTRIMS 2024 Annual Meeting

September 18 – September 20, 2024
Copenhagen, Denmark

We are excited to engage with leading experts in MS at the 2024 ECTRIMS Meeting, where we’ll have the opportunity to present our innovative approach to revolutionizing care in MS.

Octave at the 2024 ECTRIMS Product Theatre

Welcome to the Real World: Blood Based Biomarkers and their Clinical Utility in Routine Neurological Practice

Join us at the ECTRIMS 2024 Product Theatre to hear our collaborators discuss the science behind our precision care platform. 

Session Description

The promise of precision medicine, transitioning from science to practice. This session focuses on the clinical applicability and impact of a multi-protein biomarker approach using the Octave Multiple Sclerosis Disease Activity (MSDA) Blood Test. The session will present validated and practical applications of The MSDA Test in clinical settings, supported by key research and publications. Learn how this multi-protein biomarker approach contributes to establishing a baseline and improving longitudinal clinical management in MS care.

Session Details

Add Event to Calendar
Michael Sy, MD

Moderator

Associate Professor of Neurology, UC Irvine
Mitzi Joi Williams, MD

Panelist

Founding Medical Director at Joi Life Wellness MS Center, Author, Speaker and Researcher
Annette Okai, MD

Panelist

Director of Neuroimmunology & Multiple Sclerosis Research, North Texas Institute of Neurology and Headache
Gabriel Pardo, MD

Panelist

Director, OMRF Multiple Sclerosis Center of Excellence
Professor, Arthritis & Clinical Immunology Research Program
Matthew Carraro, MD

Panelist

Neurologist, Piedmont Healthcare, The Charlotte Center for MS, Lake Norman Neurology

Our 2024 ECTRIMS Poster Presentations

Discover the science behind Octave's innovative approach to precision care

Visit us during the ECTRIMS 2024 Poster Presentations, where both our Medical Team and collaborators will be presenting the following:

Poster Session 1  – Wednesday, September 18, 2024, 4:15 – 6:15 pm (16:15 – 18:15) CEST

  • (P226) Impact of MS Imaging Analytics on MRI Report Findings
  • (P344) Safety and effectiveness of cladribine tablets after treatment with natalizumab (CLADRINA trial) – 2 year results
  • (P266) Real-World Utilization of a Multi-Proteomic, Serum-Based Assay for Assessing Response to Therapy in Persons with Multiple Sclerosis

Poster Session 2 – Thursday, September 19, 2024, 4:45 – 6:45 pm (16:45 – 18:45) CEST

  • (P681) Proteomic signatures of choroid plexus changes in multiple sclerosis

Posters

  • (P1516) Comparison of Multiple Sclerosis Disease Activity (MSDA) Test Results Between Patients Treated with Ublituximab and Teriflunomide in the Phase 3 ULTIMATE I and II Studies
  • (P1478) Visualizing the topographical model of multiple sclerosis using novel 3D rendering of quantified MRI
Explore more of Our Science

Connect with the Octave Team in Copenhagen

Visit us at our booth!

We are looking forward to meeting you in Copenhagen. Please stop by our booth to say hello, and schedule time with the Octave team. 

Booth Details

  • Location: Booth 150
  • Team Availability: (TBA)
Schedule Time with Octave

Octave Highlights from MSMilan 2023

© 2024 Octave Bioscience, Inc | 1440 O’Brien Drive, Suite B, Menlo Park, CA 94025 

Connect with us